Pharma sector to grow at 13%

March 2007
Chemical Business;Mar2007, Vol. 21 Issue 3, p78
Trade Publication
The article offers information on a study by IndusView on the pharmaceutical industry in India. According to the study, the domestic pharmaceutical industry is expected to grow 13% and reach a market size of $6.5 billion. Topics discussed include low cost, high volume generic drugs, mergers and acquisitions, contract research and clinical trials, and increased integration with global trade.


Related Articles

  • Bulking up in generics. Mirasol, Feliza // Chemical Market Reporter;3/13/2006, Vol. 269 Issue 10, p18 

    The article reports on the mergers and acquisitions (M&A) of companies in the generic drug industry worldwide. In 2000, leading consolidations were Novartis' Sandoz, Teva Pharmaceuticals and Merck KGaA. Decision Resources Inc. cited the factors driving the boom of M&A activity including cost...

  • Novartis divests products for Hexal deal.  // Chemical Market Reporter;5/23/2005, Vol. 267 Issue 21, p20 

    The article informs that pharmaceutical firm Novartis AG is set to divest a handful of products in selected European markets as part of concessions made to gain approval from European regulatory authorities for Novartis's proposed acquisition of German generics company, Hexal AG. Novartis...

  • Best may be yet to come for generic drug makers. Kirsche, Michelle L. // Drug Store News;2/14/2005, Vol. 27 Issue 2, p28 

    Reports on the research-and-development pipeline of drug makers in the U.S. Sales of generic companies; Factors contributing to the performance of drug makers; Development of generic pipeline.

  • GPhA bullish on generic industry's future. Cohen, Harold E. // Drug Topics;5/7/2001, Vol. 145 Issue 9, p64 

    Provides information on the Generic Pharmaceutical Association (GPhA), a unification of the generic industry in the United States. Significance of the formation of a united front for the generic industry; Goals of the association; Strategy of pharmacy benefit managers.

  • Is the Generics Industry Ready for Multi-Source Biologics? Challener, Cynthia // Chemical Market Reporter;04/23/2001, Vol. 259 Issue 17, p14 

    Deals with the generic biologic industry. Estimated growth of the biopharmaceutical generics market; Details on the acquisition of Indiana Protein Technologies by Ivax Corp.; European firms preparing to participate in the marketing and sales of generic biopharmaceuticals; Risks faced by a...

  • SEE pharmaceutical market healthy in 2010. Stamov, Valentin; Pavlova, Iskra // SEE Top 100;2011, p46 

    The article focuses on the condition of the pharmaceutical market in 2010 in Southeast Europe (SEE). It notes that sales of pharmaceuticals in the SEE region are influenced by generic drugs. It claims that there is a growth in the pharmaceutical market in Bulgaria in terms of value. It also...

  • Antihypertensives: Generics striking at heart of the market.  // PharmaWatch: Monthly Review;Jan2007, Vol. 6 Issue 1, p13 

    The article focuses on the declining growth rate of the antihypertensive drug market in the U.S. which has been attributed to the penetration of generic drugs. It is cited that the slow growth rate does not manifest a stationary market, but a battle between generic drugs and branded ones....

  • AmerisourceBergen's focus is always on the customer.  // Chain Drug Review;7/16/2012, Vol. 34 Issue 12, p35 

    The article focuses on AmerisourceBergen Corp., which has witnessed development in the areas significant for the future of pharmacy, generic drugs, and the needs of customers and patients. AmerisourceBergen's PRxO Generics Solutions initiative and other programs have been designed to enable...

  • Apotex launches first generic version of Paxil.  // PharmaWatch: CNS;October 2003, Vol. 2 Issue 10, p10 

    Reports on the launch of the first generic version of GlaxoSmithKline's top-selling antidepressant Paxil in the U.S. by Apotex Corp. Challenges faced by Apotex in the development of the generic version of Paxil; Details of the manufacturing process of the generic drug; Capability of the company...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics